JP Morgan Chase
ADCT icon

JP Morgan Chase’s ADC Therapeutics ADCT Stock Holding History

JP Morgan Chase’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Sell
152,540
-336,539
-69% -$982K ﹤0.01% 5751
2026
Q1 		$1.78M Buy
489,079
+17,386
+4% +$68.5K ﹤0.01% 4196
2025
Q4 		$1.67M Buy
471,693
+141,096
+43% +$573K ﹤0.01% 4231
2025
Q3 		$1.32M Buy
330,597
+296,350
+865% +$934K ﹤0.01% 4382
2025
Q2 		$91.8K Sell
34,247
-5,472
-14% -$11.5K ﹤0.01% 5644
2025
Q1 		$56K Buy
39,719
+2,698
+7% +$4.58K ﹤0.01% 5841
2024
Q4 		$73.7K Sell
37,021
-41,792
-53% -$109K ﹤0.01% 5874
2024
Q3 		$248K Buy
78,813
+48,976
+164% +$154K ﹤0.01% 5310
2024
Q2 		$94.3K Buy
+29,837
New +$119K ﹤0.01% 5541
2023
Q3 		– Sell
-2,760,081
Closed -$5.93M – 7427
2023
Q2 		$5.93M Sell
2,760,081
-331,733
-11% -$746K ﹤0.01% 2724
2023
Q1 		$6.03M Buy
3,091,814
+87,348
+3% +$322K ﹤0.01% 2673
2022
Q4 		$11.5M Sell
3,004,466
-412,051
-12% -$1.65M ﹤0.01% 2126
2022
Q3 		$16.5M Sell
3,416,517
-37,155
-1% -$269K ﹤0.01% 1724
2022
Q2 		$27.5M Buy
3,453,672
+39,042
+1% +$369K ﹤0.01% 1380
2022
Q1 		$50.2M Buy
3,414,630
+219,788
+7% +$3.49M 0.01% 1164
2021
Q4 		$64.5M Sell
3,194,842
-73,144
-2% -$1.76M 0.01% 1077
2021
Q3 		$88.8M Buy
3,267,986
+69,778
+2% +$1.79M 0.01% 926
2021
Q2 		$77.9M Buy
3,198,208
+55,955
+2% +$1.3M 0.01% 1008
2021
Q1 		$76.7M Buy
3,142,253
+155,335
+5% +$4.5M 0.01% 969
2020
Q4 		$95.6M Buy
2,986,918
+898,606
+43% +$29.4M 0.01% 789
2020
Q3 		$68.6M Buy
2,088,312
+945,539
+83% +$40.9M 0.01% 836
2020
Q2 		$53.5M Buy
+1,142,773
New +$43.4M 0.01% 861

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase's ADCT Position: Q2 2026 in Review

JP Morgan Chase reduced its ADC Therapeutics (ADCT) stake by 69% in Q2 2026, selling an estimated $982K and leaving 152,540 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #5751.

JP Morgan Chase first reported a position in ADCT in Q2 2020 and has held it in 22 quarters since. The position peaked at $95.6M in Q4 2020. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • JP Morgan Chase held 152,540 shares of ADC Therapeutics worth $157K as of Q2 2026.
  • JP Morgan Chase sold 336,539 ADC Therapeutics shares in Q2 2026, an estimated $982K.
  • ADC Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5751 holding.
  • JP Morgan Chase first reported a position in ADC Therapeutics in Q2 2020 and has held it in 22 quarters since.
  • JP Morgan Chase's ADC Therapeutics position peaked at $95.6M in Q4 2020.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.